Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma

Journal of Drugs in Dermatology

Volumn 12, Issue 3, 2013, Pages 270-274

  Monheit, Gary D ^a   Dreher, Frank ^b  

^a TOTAL   (France)

^b Neocutis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPIGMENTING AGENT; FLUOCINOLONE; HYDROQUINONE; MELAPLEX; RETINOIC ACID; SUNSCREEN; TRI LUMA; UNCLASSIFIED DRUG;

ARTICLE; BURNING SENSATION; CHLOASMA; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MELANOGENESIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN ABRASION; SKIN ATROPHY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; HUMANS; HYDROQUINONES; MELANOSIS; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRETINOIN; YOUNG ADULT;

EID: 84874323762     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18(1):91-98.
2. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55(6):1048-1065. (Pubitemid 44716465)
3. Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006;19(6):550-571. (Pubitemid 44674109)
4. Picardo M, Carrera M. New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin. 2007;25(3):353-362. (Pubitemid 47088898)
5. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111(1):40-48.
6. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67-72. (Pubitemid 37229761)
7. Grimes PE. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. Cutis. 2007;80(6):497-502.
8. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308-313. (Pubitemid 350197161)
9. Levitt J. The safety of hydroquinone: a dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol. 2007;57(5):854-872. (Pubitemid 47553063)
10. McGregor D. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Crit Rev Toxicol. 2007;37(10):887-914. (Pubitemid 350135822)
11. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781-787. (Pubitemid 44102908)
12. Schallreuter KU, Kothari S, Chavan B, Spencer JD. Regulation of melanogenesis- -controversies and new concepts. Exp Dermatol. 2007;17(5):395-404.
13. Schallreuter KU, Wood JM. The importance of L-phenylalanine transport and its autocrine turnover to L-tyrosine for melanogenesis in human epidermal melanocytes. Biochem Biophys Res Comm. 1999;262(2):423-428. (Pubitemid 29429884)
14. Van Den Bossche K, Naeyaert JM, Lambert J. The quest for the mechanism of melanin transfer. Traffic. 2006;7(7):769-778. (Pubitemid 43871769)
15. Joshi PG, Nair N, Begum G, Joshi NB, Sinkar VP, Vora S. Melanocyte-keratinocyte interaction induces calcium signalling and melanin transfer to keratinocytes. Pigment Cell Res. 2007;20(5):380-384. (Pubitemid 47390112)
16. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res. 2005;571(1-2):133-152. (Pubitemid 40313438)
17. Pankovich JM, Jimbow K. Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues. Biochem J. 1991;280(Pt 3):721-725.
18. Potterf SB, Muller J, Bernardini I, et al. Characterization of a melanosomal transport system in murine melanocytes mediating entry of the melanogenic substrate tyrosine. J Biol Chem. 1996;271(8):4002-4008. (Pubitemid 26070494)
19. Ishikawa M, Kawase I, Ishii F. Combination of amino acids reduces pigmentation in B16F0 melanoma cells. Biol Pharm Bull. 2007;30(4):677-681. (Pubitemid 46570987)
20. Schmaus G, Vielhaber G, Jacobs K, Franke H. 4-(1-Phenylethyl) 1,3-benzenediol: a new highly potent lightening agent. J Cosmet Sci. 2006;57(2):197-198. (Pubitemid 43910807)
21. Stoltz C, Garcia C. Use of a compound inactivating the kinase A protein in a composition containing a cosmetically acceptable medium in order to lighten the skin. US Patent Application 2005/0118119.
22. Kimbrough-Green CK, Griffiths CE, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727-733. (Pubitemid 24182681)
23. Pandya AG, Hynan LS, Bhore R, et al. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78-83.
24. Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010;(7):CD003583.
25. Gold MH, Biron J. Efficacy of a novel hydroquinone-free skin-brightening cream in patients with melasma. J Cosmet Dermatol. 2011;10(3):189-196.
26. Nolan BV, Feldman SR. Dermatologic medication adherence. Dermatol Clin. 2009;27(2):113-120.